Metformin is the most prescribed drug for DM2, but its site and mechanism of action are still not well established. Here, we investigated the effects of metformin on basolateral intestinal glucose uptake (BIGU), and its consequences on hepatic glucose production (HGP). In diabetic patients and mice, the primary site of metformin action was the gut, increasing BIGU, evaluated through PET-CT. In mice and CaCo2 cells, this increase in BIGU resulted from an increase in GLUT1 and GLUT2, secondary to ATF4 and AMPK. In hyperglycemia, metformin increased the lactate (reducing pH and bicarbonate in portal vein) and acetate production in the gut, modulating liver pyruvate carboxylase, MPC1/2, and FBP1, establishing a gut-liver crosstalk that reduces HGP. In normoglycemia, metformin-induced increases in BIGU is accompanied by hypoglycemia in the portal vein, generating a counter-regulatory mechanism that avoids reductions or even increases HGP. In summary, metformin increases BIGU and through gut-liver crosstalk influences HGP.

Metformin acts in the gut and induces gut-liver crosstalk / N. Tobar, G.Z. Rocha, A. Santos, D. Guadagnini, H.B. Assalin, J.A. Camargo, A.E.S.S. Gonçalves, F.R. Pallis, A.G. Oliveira, S.A. Rocco, R.M. Neto, I.L. de Sousa, M.R. Alborghetti, M.L. Sforça, P.B. Rodrigues, R.G. Ludwig, E.C. Vanzela, S.Q. Brunetto, P.A. Boer, J.A.R. Gontijo, B. Geloneze, C.R.O. Carvalho, P.O. Prada, F. Folli, R. Curi, M.A. Mori, M.A.R. Vinolo, C.D. Ramos, K.G. Franchini, C.F. Tormena, M.J.A. Saad. - In: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. - ISSN 0027-8424. - 120:4(2023), pp. e2211933120.1-e2211933120.11. [10.1073/pnas.2211933120]

Metformin acts in the gut and induces gut-liver crosstalk

F. Folli
Membro del Collaboration Group
;
2023

Abstract

Metformin is the most prescribed drug for DM2, but its site and mechanism of action are still not well established. Here, we investigated the effects of metformin on basolateral intestinal glucose uptake (BIGU), and its consequences on hepatic glucose production (HGP). In diabetic patients and mice, the primary site of metformin action was the gut, increasing BIGU, evaluated through PET-CT. In mice and CaCo2 cells, this increase in BIGU resulted from an increase in GLUT1 and GLUT2, secondary to ATF4 and AMPK. In hyperglycemia, metformin increased the lactate (reducing pH and bicarbonate in portal vein) and acetate production in the gut, modulating liver pyruvate carboxylase, MPC1/2, and FBP1, establishing a gut-liver crosstalk that reduces HGP. In normoglycemia, metformin-induced increases in BIGU is accompanied by hypoglycemia in the portal vein, generating a counter-regulatory mechanism that avoids reductions or even increases HGP. In summary, metformin increases BIGU and through gut-liver crosstalk influences HGP.
Diabetes; Metformin; glucose metabolism; gut-liver crosstalk
Settore MED/13 - Endocrinologia
2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
pnas.2211933120-1.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 3.91 MB
Formato Adobe PDF
3.91 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/952880
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
social impact